

Irinotecan liposome NAPOLI 3

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



Not qualified for an ESMO-MCBS credit



#### Serious and disabling adverse effects



#### Other adjustments



Irinotecan liposome NAPOLI 3

### SCORE

#### CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma.

Experimental Arm: Irinotecan liposome + Oxaliplatin, fluorouracil, and leucovorin

Control Arm: Nab-paclitaxel + gemcitabine

